Patent ID: 9493574
Filing Date: 2016-11-15
CPC Classification: A61B,A61K,A61P,C07K

Claim Text:
1. A method of treating B-cell lymphoma, B-cell leukemia, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, or multiple myeloma disease, comprising administering to a human patient with B-cell lymphoma, B-cell leukemia, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, or multiple myeloma, an immunoconjugate comprising SN-38 conjugated to an hA19 (anti-CD19) antibody or antigen-binding fragment thereof; wherein the immunoconjugate is administered at a dosage of between 6 mg/kg and 18 mg/kg, wherein the patient has failed to respond to at least one other therapy, prior to treatment with the immunoconjugate.